Marta Ingaliso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marta Ingaliso has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Davide Taietti
Azienda Socio Sanitaria Territoriale (ASST) Ospedale Maggiore, Anatomic Pathology Unit, Crema, Italy
2 shared publications - Gabriele Gaggero
Pathology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
2 shared publications - Andrea Rossi
Neuroradiology Unit IRCCS Istituto Giannina Gaslini Genoa Italy
1 shared publication - Claudia Milanaccio
Neuro-oncology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy
1 shared publication - Gianluca Piatelli
Neurosurgery Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy
1 shared publication - Luca Carlin
Università di Genova, Scuola di Scienze Mediche e Farmaceutiche, Dipartimento di Scienze Chirurgiche e Diagnostiche integrate (DISC), Divisione di Anatomia Patologica, Genova, Italy
1 shared publication
Latest Publications
- Open Access
- 2 January 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (1) , 84-91
A Rare Pediatric Giant Cell Tumor of the Clivus Bone, H3.3 p.Gly35Trp-mutated: Case Report and Mini-review of the Literature
Introduction: Giant cell tumor of bone (GCTB) is a rare, typically benign neoplasm that primarily affects long bones in adults, with clival involvement being extremely rare, particularly in pediatric cases: a mini-review shows a total of 28 described cases, of which only 5 were truly pediatric (within 14 years of age). Surgery is the treatment of choice, and Denosumab is reported to be the most effective drug therapy. To date, the GCTB’s molecular hallmark is the somatic mutation p.Gly34Trp, at the H3F3A gene (H3.3 p.Gly34Trp mutation), but in this case, the mutation H3.3 p.Gly35Trp was identified. Case Presentation: A 9-year-old female presented with progressive ocular pain, ptosis, and diplopia. MRI revealed a 42 × 32 × 30 mm mass in the clivus and sphenoid body. The patient underwent partial resection, and histology confirmed GCTB. Molecular testing revealed the presence of the H3.3 p.Gly35Trp mutation, and we demonstrate that this is the true mutation associated with GCTB, not the previously described (H3.3 p.Gly34Trp). Due to residual tumor tissue, the patient was treated with Denosumab, a RANKL inhibitor. During a 2-year follow-up, the tumor size stabilized, and no significant adverse effects were observed. Conclusion: This case represents the first pediatric clival GCTB harboring the H3.3 p.Gly35Trp mutation. Molecular diagnostics played a crucial role in confirming the diagnosis and demonstrating that the true mutation harbored by GCTB is H3.3 p.Gly35Trp and not the formerly described (H3.3 p.Gly34Trp). Denosumab therapy effectively controlled the tumor without major side effects, although long-term treatment duration and safety require further study. Cite this article as: Gaggero G, Battaglia T, Andreotti V, et al. A rare pediatric giant cell tumor of the clivus bone, H3.3 p.Gly35Trp-mutated: case report and mini-review of the literature. Turk Arch Pediatr. 2025;60(1):84-91.
- 2 January 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (1) , 84-91
Open AccessA Rare Pediatric Giant Cell Tumor of the Clivus Bone, H3.3 p.Gly35Trp-mutated: Case Report and Mini-review of the Literature
Introduction: Giant cell tumor of bone (GCTB) is a rare, typically benign neoplasm that primarily affects long bones in adults, with clival involvement being extremely rare, particularly in pediatric cases: a mini-review shows a total of 28 described cases, of which only 5 were truly pediatric (within 14 years of age). Surgery is the treatment of choice, and Denosumab is reported to be the most effective drug therapy. To date, the GCTB’s molecular hallmark is the somatic mutation p.Gly34Trp, at the H3F3A gene (H3.3 p.Gly34Trp mutation), but in this case, the mutation H3.3 p.Gly35Trp was identified. Case Presentation: A 9-year-old female presented with progressive ocular pain, ptosis, and diplopia. MRI revealed a 42 × 32 × 30 mm mass in the clivus and sphenoid body. The patient underwent partial resection, and histology confirmed GCTB. Molecular testing revealed the presence of the H3.3 p.Gly35Trp mutation, and we demonstrate that this is the true mutation associated with GCTB, not the previously described (H3.3 p.Gly34Trp). Due to residual tumor tissue, the patient was treated with Denosumab, a RANKL inhibitor. During a 2-year follow-up, the tumor size stabilized, and no significant adverse effects were observed. Conclusion: This case represents the first pediatric clival GCTB harboring the H3.3 p.Gly35Trp mutation. Molecular diagnostics played a crucial role in confirming the diagnosis and demonstrating that the true mutation harbored by GCTB is H3.3 p.Gly35Trp and not the formerly described (H3.3 p.Gly34Trp). Denosumab therapy effectively controlled the tumor without major side effects, although long-term treatment duration and safety require further study. Cite this article as: Gaggero G, Battaglia T, Andreotti V, et al. A rare pediatric giant cell tumor of the clivus bone, H3.3 p.Gly35Trp-mutated: case report and mini-review of the literature. Turk Arch Pediatr. 2025;60(1):84-91.
- Open Access
- 1 January 2022
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 12, e2021408
Gastric undifferentiated carcinoma, INI1-negative
Autops Case Rep, vol.12, e2021408, 2022
- 1 January 2022
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 12, e2021408
Open AccessGastric undifferentiated carcinoma, INI1-negative
Autops Case Rep, vol.12, e2021408, 2022